Indexed In : Science Citation Index Expanded(SCIE), MEDLINE,
Pubmed/Pubmed Central, Elsevier Bibliographic, Google Scholar,
Databases(Scopus & Embase), KCI, KoreaMed, DOAJ
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Cheal Wung Huh1, Gi Jun Kim1, Byung-Wook Kim1 , Myeongsook Seo2, Joon Sung Kim1
Correspondence to: Byung-Wook Kim
Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 56 Dongsu-ro, Bupyeong-gu, Incheon 21431, Korea
Tel: +82-32-280-5052, Fax: +82-32-280-5987, E-mail: gastro@catholic.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut Liver 2019;13(5):515-521. https://doi.org/10.5009/gnl18350
Published online May 27, 2019, Published date September 15, 2019
Copyright © Gut and Liver.
The risk of peritoneal seeding following perforation after endoscopic resection in patients with early gastric cancer is unclear. The purpose of this study was to investigate long-term clinical outcomes including peritoneal seeding and overall survival rate following gastric perforation during endoscopic submucosal dissection (ESD). Between January 2002 and March 2015, 556 patients were diagnosed with early gastric cancer and underwent ESD. Among them, 34 patients (6.1%) experienced gastric perforation during ESD. Clinicopathological data of these patients were reviewed to determine the clinical outcome and evidence of peritoneal seeding. Among 34 patients with perforation, macroperforations occurred during ESD in 17 cases (50%), and microperforation was identified in the remaining 17 cases (50%). All patients except one who underwent emergency surgery due to severe panperitonitis were managed successfully by endoscopic clipping (n=27) or conservative medical treatment (n=6). No evidence of peritoneal seeding after perforation associated with ESD was found in our cohort. Cumulative survival rates did not differ between the perforation and non-perforation groups (p=0.691). Furthermore, mortality was not associated with perforation. In addition, multivariate analysis showed that tumor size and achievement of curative resection were related to cancer recurrence. Perforation was not associated with cancer recurrence and survival. Perforation associated with ESD does not lead to worse clinical outcomes such as peritoneal seeding or cumulative survival rate. Therefore, periodic follow-up might be possible if curative resection was achieved even if perforation occurred during ESD.Background/Aims
Methods
Results
Conclusions
Keywords: Endoscopic submucosal dissection, Perforation, Peritoneal seeding, Early gastric cancer
Endoscopic submucosal dissection (ESD) has been recognized as a standard treatment for selected cases of early gastric cancer in Korea.1,2 Compared to surgery, ESD has advantages in that it can preserve the stomach with relatively non-invasive technique. In addition, ESD can promote high rates of
Perforation is a major complication of ESD. The incidence of ESD-related perforation has been reported to be about 1.2% to 6.1%.6–8 Recently, it has been reported that most perforations caused by ESD could be treated with immediate endoscopic clipping and without additional surgery.9 However, the clinical course after perforation must be taken into consideration, including peritoneal seeding.10,11 The possibility of disseminating cancer cells into the peritoneal cavity is a potential drawback associated with minimal invasive procedure such as ESD.
Whether perforation associated with endoscopic resection causes peritoneal seeding during ESD has been controversial.10,12 Therefore, the objective of this study was to investigate long-term clinical outcomes including peritoneal seeding and overall survival rate following gastric perforation during ESD.
Between January 2002 and March 2015, 556 patients who were diagnosed with early gastric cancer underwent ESD at Incheon St. Mary’s Hospital, The Catholic University of Korea. Among them, 34 patients (6.1%) experienced gastric perforation during ESD. Clinicopathological data of these 34 patients were reviewed. The Institutional Review Board of The Catholic University of Korea approved this study. The informed consent was waived due to retrospective design.
All ESD procedures were performed by two expert endoscopists (B.W.K. and J.S.K.). After patients were moderately sedated with midazolam and propofol, ESD was performed. A video endoscope with or without a water-jet function (GIF-HQ290, GIF-Q260, GIF-H260; Olympus, Tokyo, Japan) was routinely used. A disposable distal transparent cap (D-201-11804; Olympus) was mounted on the tip of the endoscope in all cases. Carbon dioxide or air was used for the insufflation. To identify target lesion, chromoendoscopy with indigo carmine solution or narrow band imaging with or without magnification was used. Following circumferential marking (using argon plasma coagulation), a mixture of indigo carmine, diluted epinephrine (1:200,000), and 10% glycerol (Cerol; JW Pharmaceutical Co., Seoul, Korea) was used to inject submucosa as marked. Epinephrine (1:1,000, total epinephrine 1 mg) was mixed in a 200-mL container of glycerol, and 8 mL of the solution was drawn into 10-mL disposable syringe to use for gastric lesion. After injection, an initial incision was made outside the marks with a dual knife or a hook knife. A knife was inserted into the initial incision, and electrosurgical current was applied with the use of an electrosurgical unit (VIO300D; Endocut I mode, effect 2; ERBE, Tubingen, Germany) to complete the circumferential mucosal incision around the lesion and submucosal dissection. The ESD procedure was performed mainly with a dual knife (KD-650Q; Olympus), an IT-knife 2 (KD-610L; Olympus), or a hook knife (KD-620LR; Olympus). Hemostatic forceps (Coagrasper, FD-410LR; Olympus) with a soft coagulation mode (VIO300D; Soft coag mode, effect 4; ERBE) were used to control bleeding during the procedure. In the case of macroperforation, perforation site was closed with endoclips (EZ clip; Olympus) using single closure methods. Even if there was no macroperforation, preventive clipping was performed when lesion was considered to be dissected deeply.
Perforation was classified into two types; macroperforation was defined as a gross defect noted during endoscopic procedure; microperforation was identified as a pneumoperitoneum by radiological evidence after the procedure without gross defect during the procedure. We defined curative resection according to the Japanese gastric cancer treatment guidelines as follows:
After ESD, follow-up consisted of endoscopic examination at three months and biannually thereafter for 2 years followed by annual follow-up to check local or metachronous recurrence. Annual abdominal computed tomography (CT) was performed to determine extragastric recurrence. We defined “follow-up loss” as the follow-up period of less than 1 year.
Between-group comparisons of clinical characteristics were conducted using the chi-square or Fisher exact test, and applying the Student t-test for non-categorical variables. Clinicopathologic factors associated with cancer recurrence were evaluated by logistic regression analysis. The Kaplan-Meier method was used to determine cumulative survival rate and the log-rank test was used to analyze differences in survival curve. The descriptive statistics were used for continuous variables. Accepted significance level was set at p-value <0.05. All statistical analyses were performed using SPSS version 20.0 for Windows (IBM Corp., Armonk, NY, USA).
Among 556 patients who were diagnosed with early gastric cancer and underwent ESD at Incheon St. Mary’s Hospital, 17 patients were excluded due to follow-up loss. Median follow-up was 51.9±27.5 months (range, 12.2 to 166.1 months). Age, sex, tumor size, macroscopic type, histology, lymphovascular invasion, curative resection, and cancer recurrence did not differ between non-perforation and perforation groups (Table 1). However, tumor location (middle and upper location) and depth of invasion (SM2 invasion) showed statistically significant associations with perforation. In perforation group, macroperforation occurred in 17 cases during ESD while microperforation occurred in the remaining 17 cases. Perforation during ESD was treated immediately by endoscopic clipping for 27 patients. One patient who suffered from panperitonitis after ESD subsequently underwent emergency surgery (wedge resection and primary repair). The remaining six patients received conservative medical treatment without endoscopic clipping or emergency surgery.
Clinical outcomes of patients with macro- and micro- perforation are shown in Fig. 1. Of 34 patients, seven patients had non-curative resection while one patient had peritoneal seeding during follow-up. Table 2 shows the characteristics of these seven patients with non-curative resection. Three patients refused additional surgery while three patients underwent additional surgery (gastrectomy and lymph node dissection). One patient (patient 5) who suffered from panperitonitis after ESD subsequently underwent emergency surgery (wedge resection and simple closure without lymph node dissection). The final pathology of resected specimen revealed submucosal invasion with depth of 4,000 μm. The patient was recommended to undergo additional surgery including lymph node dissection. However, the patient refused our suggestion at that time. Two years later, the patient showed massive retroperitoneal metastatic lymphadenopathy and tumor seeding with neck and brain metastasis on follow-up CT.
Univariate and multivariate analyses were performed to identify factors associated with cancer recurrence (Tables 3 and 4). Multivariate analysis showed that tumor size and achievement of curative resection were related to cancer recurrence (Table 4). Perforation was not associated with cancer recurrence.
We excluded patients who underwent additional surgery after non-curative resection (non-perforation group, n=43 and perforation group, n=4). The Kaplan-Meier analysis indicated that patients with perforation had similar cumulative survival rate compared to those with non-perforation in our cohort (Fig. 2). There was no mortality associated with perforation.
The overall frequency of perforation found in our study was 6.1% (microperforation, 50% and macroperforation, 50%), consistent with previous reports.6–8 Overall cumulative survival rate did not differ between perforation and non-perforation groups with median follow up of 51.9±27.5 months. There was no evidence of peritoneal seeding after a perforation associated with ESD in this study.
Perforation is a major complication of ESD. It is related to significant morbidity and mortality. In some cases, emergency surgery is required and the risk of peritoneal seeding should be considered.7,9 Peritoneal seeding following fine needle biopsy for hepatocellular carcinoma and port-site seeding after laparoscopic surgery have been reported.14,15 Theoretically, perforation of the gastric wall in a lesion containing cancer cells during ESD may lead to peritoneal seeding.
Two studies have reported the risk of peritoneal seeding after perforation during gastric endoscopic resection to date. In a retrospective study of 90 patients with perforation after gastric endoscopic resection, there was no peritoneal seeding.12 A recent retrospective study has reported peritoneal seeding occurring in two of 22 patients with perforation following gastric endoscopic resection.10 In this previous study, the ESD specimen of one patient had pathologic vertical margin positive and deep SM invasion. Another patient with mucosal cancer underwent emergency surgery for acute peritonitis. However, several clinicopathological characteristics (e.g., curative resection, depth of invasion, type of additive operation, etc.) of these two patients could not be verified. A case of peritoneal seeding after perforation during ESD has also been reported.11 In this case, however, cancer cell existed in muscularis propria layer in the ESD specimen. Therefore, it is unclear whether peritoneal seeding and perforation during ESD are directly linked. Furthermore, previous studies have several limitations such as relatively short-term follow-up period and lack of clinicopathological characteristics (e.g., curative resection, depth of invasion, survival rate, etc.).
To overcome such limitations, the present study was conducted with relatively long-term follow-up period. In addition, several clinicopathological factors including cumulative survival rate were validated. Our results revealed that gastric perforation during ESD did not lead to peritoneal dissemination, even in the long term. Cumulative survival rates did not differ between perforation and non-perforation groups either. In the perforation group, one patient displayed massive retroperitoneal metastatic lymphadenopathy and tumor seeding with neck and brain metastasis on follow-up CT. Although peritoneal recurrence occurred in this patient, it might not be related to perforation during ESD. The patient strongly refused additional surgery including lymph node dissection. Several studies have reported that lymph node metastasis can occur in 3.4% to 9.3% of patients after undergoing additive surgery following non-curative resection.16–19 Thus, it is reasonable to consider the case as a multiple organ metastasis from perilesional lymph node metastasis. Although the lack of peritoneal sampling was a major limitation of the present study, this case was not peritoneal seeding due to perforation.
In our study, the perforation group and the non-perforation group showed similar cumulative survival rates even in the long term. In addition, perforation was not associated with cancer recurrence. Our results suggest that perforation associated with ESD procedure could be successfully managed using non-surgical method (e.g., endoscopic clipping and conservative care). In addition, if resected lesion meets “curative resection,” periodic follow-up could be allowed regardless of perforation.
Our study has several limitations. First, this was a retrospective study which restricted our ability to control certain aspects of the study. Second, we did not perform peritoneal lavage in patients with perforation. Third, the number of perforations was relatively small due to low rates of perforation. Nevertheless, our study has the strength of long-term follow up for clinical courses of patients with perforation.
In conclusion, results of this study demonstrated that perforation during ESD was not accompanied by worse clinical outcome such as peritoneal seeding and cumulative survival rate. Therefore, periodic follow-up is possible if curative resection is achieved regardless of perforation during ESD.
No potential conflict of interest relevant to this article was reported.
Conception and design of the study: B.W.K. Data analysis and interpretation: C.W.H., G.J.K., M.S. Drafting of the manuscript: C.W.H. Critical revision of the manuscript for important intellectual content: J.S.K. Approval of the final version of the manuscript: all authors.
See editorial on page 481.
ESD, endoscopic submucosal dissection.
Clinicopathologic Characteristics and Clinical Outcomes between the Non-perforation and Perforation Groups
Characteristics | Non-perforation group (n=505) | Perforation group (n=34) | p-value |
---|---|---|---|
Age, yr | 66.3±10.1 | 64.3±8.2 | 0.230 |
Sex, male:female | 358:147 | 27:7 | 0.287 |
Tumor location | <0.001 | ||
Upper | 29 (5.7) | 6 (17.6) | |
Middle | 108 (21.4) | 19 (55.9) | |
Lower | 368 (72.9) | 9 (26.5) | |
Tumor size, mm | 0.516 | ||
<20 | 288 (57.0) | 16 (47.1) | |
20–30 | 149 (29.5) | 12 (35.3) | |
>30 | 68 (13.5) | 6 (17.6) | |
Macroscopic type | 0.405 | ||
Elevated | 196 (38.8) | 17 (50.0) | |
Flat | 143 (28.3) | 7 (20.6) | |
Depressed | 166 (32.9) | 10 (29.4) | |
Histology | 0.481 | ||
Differentiated | 457 (90.5) | 32 (94.1) | |
Undifferentiated | 48 (9.5) | 2 (5.9) | |
Depth of invasion | |||
Mucosa | 430 (85.2) | 25 (73.5) | 0.010 |
SM1 (<500 µm) | 42 (8.3) | 2 (5.9) | |
SM2 (≥500 µm) | 33 (6.5) | 7 (20.6) | |
Lymphovascular invasion | 0.350 | ||
Absent | 469 (92.9) | 33 (97.1) | |
Present | 36 (7.1) | 1 (2.9) | |
Curative resection | 0.287 | ||
Yes | 358 (70.9) | 27 (79.4) | |
No | 147 (29.1) | 7 (20.6) | |
Additive surgery | 50 (9.9) | 4 (11.8) | 0.726 |
Recurrence | 29 (5.7) | 1 (2.9) | 0.490 |
Local recurrence | 28 | 0 | |
Extragastric recurrence | 1 | 1 | |
Perforation | - | - | |
Macroperforation | 17 (50.0) | ||
Microperforation | 17 (50.0) | ||
Treatment of perforation | - | - | |
Endoscopic clipping | 27 (79.4) | ||
Emergency surgery | 1 (2.9) | ||
Conservative care | 6 (17.7) |
Data are presented as mean±SD or number (%).
SM, submucosa.
Characteristics of Patients with Non-curative Endoscopic Resection (n=7)
Variable | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
---|---|---|---|---|---|---|---|
Sex | Male | Female | Male | Female | Male | Male | Male |
Age, yr | 56 | 49 | 64 | 62 | 71 | 62 | 64 |
Tumor location | Middle | Lower | Middle | Upper | Middle | Middle | Middle |
Tumor size, mm | 15 | 15 | 5 | 20 | 24 | 32 | 32 |
Histology | Differentiated | Differentiated | Differentiated | Differentiated | Differentiated | Differentiated | Undifferentiated |
Non-curative factor | SM2 invasion | LM positive | SM2 invasion | SM2 invasion | SM2 invasion | LM positive | SM2 invasion |
Resection type | |||||||
Perforation | Microperforation | Microperforation | Microperforation | Macroperforation | Macroperforation | Macroperforation | Macroperforation |
Management of perforation | Conservative care | Endoscopic clipping | Endoscopic clipping | Endoscopic clipping | Emergency operation (wedge resection and primary repair) | Endoscopic clipping | Endoscopic clipping |
Treatment after NCR | Refusing surgery | Refusing surgery | Additive surgery (gastrectomy with LN dissection) | Refusing surgery | Emergency operation (wedge resection and primary repair) | Additive surgery (gastrectomy with LN dissection) | Additive surgery (gastrectomy with LN dissection) |
Follow-up, mo | 98 | 59 | 49 | 84 | 28 | 51 | 36 |
Recurrence | No | No | No | No | Yes | No | No |
Peritoneal seeding | No | No | No | No | Yes | No | No |
Survival | Yes | Yes | Yes | Yes | No | Yes | Yes |
SM, submucosa; LM, lateral margin; NCR, non-curative resection; LN, lymph node.
Univariate Analysis of Clinicopathologic Characteristics Associated with Cancer Recurrence
Characteristic | No recurrence (n=509) |
Recurrence (n=30) |
p-value |
---|---|---|---|
Age, yr | 0.143 | ||
<65 | 222 (43.6) | 9 (30.0) | |
≥65 | 287 (56.4) | 21 (70.0) | |
Sex, male:female | 363:146 | 22:8 | 0.812 |
Tumor location | 0.083 | ||
Upper | 31 (6.1) | 4 (13.3) | |
Middle | 124 (24.4) | 3 (10.0) | |
Lower | 354 (69.5) | 23 (76.7) | |
Tumor size, mm | <0.001 | ||
<20 | 301 (59.1) | 3 (10.0) | |
20–30 | 143 (28.1) | 18 (60.0) | |
>30 | 65 (12.8) | 9 (30.0) | |
Macroscopic type | 0.197 | ||
Elevated | 201 (39.5) | 12 (40.0) | |
Flat | 138 (27.1) | 12 (40.0) | |
Depressed | 170 (33.4) | 6 (20.0) | |
Histology | 0.431 | ||
Differentiated | 463 (91.0) | 26 (86.7) | |
Undifferentiated | 46 (9.0) | 4 (13.3) | |
Depth of invasion | |||
Mucosa | 431 (84.6) | 24 (80.0) | 0.783 |
SM1 (<500 µm) | 41 (8.1) | 3 (10.0) | |
SM2 (≥500 µm) | 37 (7.3) | 3 (10.0) | |
Lymphovascular invasion | 0.431 | ||
Absent | 473 (92.9) | 29 (96.7) | |
Present | 36 (7.1) | 1 (3.3) | |
Curative resection | <0.001 | ||
Yes | 374 (73.5) | 11 (36.7) | |
No | 135 (26.5) | 19 (63.3) | |
Perforation | |||
Yes | 33 (6.5) | 1 (3.3) | 0.490 |
No | 476 (93.5) | 29 (96.7) |
Data are presented as number (%).
SM, submucosa.
Multivariate Analysis of Clinicopathologic Characteristics Associated with Cancer Recurrence
Characteristic | OR (95% CI) | p-value |
---|---|---|
Tumor size, mm | ||
<20 | Reference | - |
20–30 | 9.97 (2.83–35.07) | <0.001 |
>30 | 8.17 (2.01–33.19) | 0.003 |
Curative resection | ||
Yes | Reference | - |
No | 2.73 (1.20–6.25) | 0.017 |
OR, odds ratio; CI, confidence interval.
Gut and Liver 2019; 13(5): 515-521
Published online September 15, 2019 https://doi.org/10.5009/gnl18350
Copyright © Gut and Liver.
Cheal Wung Huh1, Gi Jun Kim1, Byung-Wook Kim1 , Myeongsook Seo2, Joon Sung Kim1
1Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, and 2Department of Internal Medicine, Konkuk University Chungju Hospital, Chungju, Korea
Correspondence to:Byung-Wook Kim
Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 56 Dongsu-ro, Bupyeong-gu, Incheon 21431, Korea
Tel: +82-32-280-5052, Fax: +82-32-280-5987, E-mail: gastro@catholic.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The risk of peritoneal seeding following perforation after endoscopic resection in patients with early gastric cancer is unclear. The purpose of this study was to investigate long-term clinical outcomes including peritoneal seeding and overall survival rate following gastric perforation during endoscopic submucosal dissection (ESD). Between January 2002 and March 2015, 556 patients were diagnosed with early gastric cancer and underwent ESD. Among them, 34 patients (6.1%) experienced gastric perforation during ESD. Clinicopathological data of these patients were reviewed to determine the clinical outcome and evidence of peritoneal seeding. Among 34 patients with perforation, macroperforations occurred during ESD in 17 cases (50%), and microperforation was identified in the remaining 17 cases (50%). All patients except one who underwent emergency surgery due to severe panperitonitis were managed successfully by endoscopic clipping (n=27) or conservative medical treatment (n=6). No evidence of peritoneal seeding after perforation associated with ESD was found in our cohort. Cumulative survival rates did not differ between the perforation and non-perforation groups (p=0.691). Furthermore, mortality was not associated with perforation. In addition, multivariate analysis showed that tumor size and achievement of curative resection were related to cancer recurrence. Perforation was not associated with cancer recurrence and survival. Perforation associated with ESD does not lead to worse clinical outcomes such as peritoneal seeding or cumulative survival rate. Therefore, periodic follow-up might be possible if curative resection was achieved even if perforation occurred during ESD.Background/Aims
Methods
Results
Conclusions
Keywords: Endoscopic submucosal dissection, Perforation, Peritoneal seeding, Early gastric cancer
Endoscopic submucosal dissection (ESD) has been recognized as a standard treatment for selected cases of early gastric cancer in Korea.1,2 Compared to surgery, ESD has advantages in that it can preserve the stomach with relatively non-invasive technique. In addition, ESD can promote high rates of
Perforation is a major complication of ESD. The incidence of ESD-related perforation has been reported to be about 1.2% to 6.1%.6–8 Recently, it has been reported that most perforations caused by ESD could be treated with immediate endoscopic clipping and without additional surgery.9 However, the clinical course after perforation must be taken into consideration, including peritoneal seeding.10,11 The possibility of disseminating cancer cells into the peritoneal cavity is a potential drawback associated with minimal invasive procedure such as ESD.
Whether perforation associated with endoscopic resection causes peritoneal seeding during ESD has been controversial.10,12 Therefore, the objective of this study was to investigate long-term clinical outcomes including peritoneal seeding and overall survival rate following gastric perforation during ESD.
Between January 2002 and March 2015, 556 patients who were diagnosed with early gastric cancer underwent ESD at Incheon St. Mary’s Hospital, The Catholic University of Korea. Among them, 34 patients (6.1%) experienced gastric perforation during ESD. Clinicopathological data of these 34 patients were reviewed. The Institutional Review Board of The Catholic University of Korea approved this study. The informed consent was waived due to retrospective design.
All ESD procedures were performed by two expert endoscopists (B.W.K. and J.S.K.). After patients were moderately sedated with midazolam and propofol, ESD was performed. A video endoscope with or without a water-jet function (GIF-HQ290, GIF-Q260, GIF-H260; Olympus, Tokyo, Japan) was routinely used. A disposable distal transparent cap (D-201-11804; Olympus) was mounted on the tip of the endoscope in all cases. Carbon dioxide or air was used for the insufflation. To identify target lesion, chromoendoscopy with indigo carmine solution or narrow band imaging with or without magnification was used. Following circumferential marking (using argon plasma coagulation), a mixture of indigo carmine, diluted epinephrine (1:200,000), and 10% glycerol (Cerol; JW Pharmaceutical Co., Seoul, Korea) was used to inject submucosa as marked. Epinephrine (1:1,000, total epinephrine 1 mg) was mixed in a 200-mL container of glycerol, and 8 mL of the solution was drawn into 10-mL disposable syringe to use for gastric lesion. After injection, an initial incision was made outside the marks with a dual knife or a hook knife. A knife was inserted into the initial incision, and electrosurgical current was applied with the use of an electrosurgical unit (VIO300D; Endocut I mode, effect 2; ERBE, Tubingen, Germany) to complete the circumferential mucosal incision around the lesion and submucosal dissection. The ESD procedure was performed mainly with a dual knife (KD-650Q; Olympus), an IT-knife 2 (KD-610L; Olympus), or a hook knife (KD-620LR; Olympus). Hemostatic forceps (Coagrasper, FD-410LR; Olympus) with a soft coagulation mode (VIO300D; Soft coag mode, effect 4; ERBE) were used to control bleeding during the procedure. In the case of macroperforation, perforation site was closed with endoclips (EZ clip; Olympus) using single closure methods. Even if there was no macroperforation, preventive clipping was performed when lesion was considered to be dissected deeply.
Perforation was classified into two types; macroperforation was defined as a gross defect noted during endoscopic procedure; microperforation was identified as a pneumoperitoneum by radiological evidence after the procedure without gross defect during the procedure. We defined curative resection according to the Japanese gastric cancer treatment guidelines as follows:
After ESD, follow-up consisted of endoscopic examination at three months and biannually thereafter for 2 years followed by annual follow-up to check local or metachronous recurrence. Annual abdominal computed tomography (CT) was performed to determine extragastric recurrence. We defined “follow-up loss” as the follow-up period of less than 1 year.
Between-group comparisons of clinical characteristics were conducted using the chi-square or Fisher exact test, and applying the Student t-test for non-categorical variables. Clinicopathologic factors associated with cancer recurrence were evaluated by logistic regression analysis. The Kaplan-Meier method was used to determine cumulative survival rate and the log-rank test was used to analyze differences in survival curve. The descriptive statistics were used for continuous variables. Accepted significance level was set at p-value <0.05. All statistical analyses were performed using SPSS version 20.0 for Windows (IBM Corp., Armonk, NY, USA).
Among 556 patients who were diagnosed with early gastric cancer and underwent ESD at Incheon St. Mary’s Hospital, 17 patients were excluded due to follow-up loss. Median follow-up was 51.9±27.5 months (range, 12.2 to 166.1 months). Age, sex, tumor size, macroscopic type, histology, lymphovascular invasion, curative resection, and cancer recurrence did not differ between non-perforation and perforation groups (Table 1). However, tumor location (middle and upper location) and depth of invasion (SM2 invasion) showed statistically significant associations with perforation. In perforation group, macroperforation occurred in 17 cases during ESD while microperforation occurred in the remaining 17 cases. Perforation during ESD was treated immediately by endoscopic clipping for 27 patients. One patient who suffered from panperitonitis after ESD subsequently underwent emergency surgery (wedge resection and primary repair). The remaining six patients received conservative medical treatment without endoscopic clipping or emergency surgery.
Clinical outcomes of patients with macro- and micro- perforation are shown in Fig. 1. Of 34 patients, seven patients had non-curative resection while one patient had peritoneal seeding during follow-up. Table 2 shows the characteristics of these seven patients with non-curative resection. Three patients refused additional surgery while three patients underwent additional surgery (gastrectomy and lymph node dissection). One patient (patient 5) who suffered from panperitonitis after ESD subsequently underwent emergency surgery (wedge resection and simple closure without lymph node dissection). The final pathology of resected specimen revealed submucosal invasion with depth of 4,000 μm. The patient was recommended to undergo additional surgery including lymph node dissection. However, the patient refused our suggestion at that time. Two years later, the patient showed massive retroperitoneal metastatic lymphadenopathy and tumor seeding with neck and brain metastasis on follow-up CT.
Univariate and multivariate analyses were performed to identify factors associated with cancer recurrence (Tables 3 and 4). Multivariate analysis showed that tumor size and achievement of curative resection were related to cancer recurrence (Table 4). Perforation was not associated with cancer recurrence.
We excluded patients who underwent additional surgery after non-curative resection (non-perforation group, n=43 and perforation group, n=4). The Kaplan-Meier analysis indicated that patients with perforation had similar cumulative survival rate compared to those with non-perforation in our cohort (Fig. 2). There was no mortality associated with perforation.
The overall frequency of perforation found in our study was 6.1% (microperforation, 50% and macroperforation, 50%), consistent with previous reports.6–8 Overall cumulative survival rate did not differ between perforation and non-perforation groups with median follow up of 51.9±27.5 months. There was no evidence of peritoneal seeding after a perforation associated with ESD in this study.
Perforation is a major complication of ESD. It is related to significant morbidity and mortality. In some cases, emergency surgery is required and the risk of peritoneal seeding should be considered.7,9 Peritoneal seeding following fine needle biopsy for hepatocellular carcinoma and port-site seeding after laparoscopic surgery have been reported.14,15 Theoretically, perforation of the gastric wall in a lesion containing cancer cells during ESD may lead to peritoneal seeding.
Two studies have reported the risk of peritoneal seeding after perforation during gastric endoscopic resection to date. In a retrospective study of 90 patients with perforation after gastric endoscopic resection, there was no peritoneal seeding.12 A recent retrospective study has reported peritoneal seeding occurring in two of 22 patients with perforation following gastric endoscopic resection.10 In this previous study, the ESD specimen of one patient had pathologic vertical margin positive and deep SM invasion. Another patient with mucosal cancer underwent emergency surgery for acute peritonitis. However, several clinicopathological characteristics (e.g., curative resection, depth of invasion, type of additive operation, etc.) of these two patients could not be verified. A case of peritoneal seeding after perforation during ESD has also been reported.11 In this case, however, cancer cell existed in muscularis propria layer in the ESD specimen. Therefore, it is unclear whether peritoneal seeding and perforation during ESD are directly linked. Furthermore, previous studies have several limitations such as relatively short-term follow-up period and lack of clinicopathological characteristics (e.g., curative resection, depth of invasion, survival rate, etc.).
To overcome such limitations, the present study was conducted with relatively long-term follow-up period. In addition, several clinicopathological factors including cumulative survival rate were validated. Our results revealed that gastric perforation during ESD did not lead to peritoneal dissemination, even in the long term. Cumulative survival rates did not differ between perforation and non-perforation groups either. In the perforation group, one patient displayed massive retroperitoneal metastatic lymphadenopathy and tumor seeding with neck and brain metastasis on follow-up CT. Although peritoneal recurrence occurred in this patient, it might not be related to perforation during ESD. The patient strongly refused additional surgery including lymph node dissection. Several studies have reported that lymph node metastasis can occur in 3.4% to 9.3% of patients after undergoing additive surgery following non-curative resection.16–19 Thus, it is reasonable to consider the case as a multiple organ metastasis from perilesional lymph node metastasis. Although the lack of peritoneal sampling was a major limitation of the present study, this case was not peritoneal seeding due to perforation.
In our study, the perforation group and the non-perforation group showed similar cumulative survival rates even in the long term. In addition, perforation was not associated with cancer recurrence. Our results suggest that perforation associated with ESD procedure could be successfully managed using non-surgical method (e.g., endoscopic clipping and conservative care). In addition, if resected lesion meets “curative resection,” periodic follow-up could be allowed regardless of perforation.
Our study has several limitations. First, this was a retrospective study which restricted our ability to control certain aspects of the study. Second, we did not perform peritoneal lavage in patients with perforation. Third, the number of perforations was relatively small due to low rates of perforation. Nevertheless, our study has the strength of long-term follow up for clinical courses of patients with perforation.
In conclusion, results of this study demonstrated that perforation during ESD was not accompanied by worse clinical outcome such as peritoneal seeding and cumulative survival rate. Therefore, periodic follow-up is possible if curative resection is achieved regardless of perforation during ESD.
No potential conflict of interest relevant to this article was reported.
Conception and design of the study: B.W.K. Data analysis and interpretation: C.W.H., G.J.K., M.S. Drafting of the manuscript: C.W.H. Critical revision of the manuscript for important intellectual content: J.S.K. Approval of the final version of the manuscript: all authors.
See editorial on page 481.
ESD, endoscopic submucosal dissection.
Table 1 Clinicopathologic Characteristics and Clinical Outcomes between the Non-perforation and Perforation Groups
Characteristics | Non-perforation group (n=505) | Perforation group (n=34) | p-value |
---|---|---|---|
Age, yr | 66.3±10.1 | 64.3±8.2 | 0.230 |
Sex, male:female | 358:147 | 27:7 | 0.287 |
Tumor location | <0.001 | ||
Upper | 29 (5.7) | 6 (17.6) | |
Middle | 108 (21.4) | 19 (55.9) | |
Lower | 368 (72.9) | 9 (26.5) | |
Tumor size, mm | 0.516 | ||
<20 | 288 (57.0) | 16 (47.1) | |
20–30 | 149 (29.5) | 12 (35.3) | |
>30 | 68 (13.5) | 6 (17.6) | |
Macroscopic type | 0.405 | ||
Elevated | 196 (38.8) | 17 (50.0) | |
Flat | 143 (28.3) | 7 (20.6) | |
Depressed | 166 (32.9) | 10 (29.4) | |
Histology | 0.481 | ||
Differentiated | 457 (90.5) | 32 (94.1) | |
Undifferentiated | 48 (9.5) | 2 (5.9) | |
Depth of invasion | |||
Mucosa | 430 (85.2) | 25 (73.5) | 0.010 |
SM1 (<500 µm) | 42 (8.3) | 2 (5.9) | |
SM2 (≥500 µm) | 33 (6.5) | 7 (20.6) | |
Lymphovascular invasion | 0.350 | ||
Absent | 469 (92.9) | 33 (97.1) | |
Present | 36 (7.1) | 1 (2.9) | |
Curative resection | 0.287 | ||
Yes | 358 (70.9) | 27 (79.4) | |
No | 147 (29.1) | 7 (20.6) | |
Additive surgery | 50 (9.9) | 4 (11.8) | 0.726 |
Recurrence | 29 (5.7) | 1 (2.9) | 0.490 |
Local recurrence | 28 | 0 | |
Extragastric recurrence | 1 | 1 | |
Perforation | - | - | |
Macroperforation | 17 (50.0) | ||
Microperforation | 17 (50.0) | ||
Treatment of perforation | - | - | |
Endoscopic clipping | 27 (79.4) | ||
Emergency surgery | 1 (2.9) | ||
Conservative care | 6 (17.7) |
Data are presented as mean±SD or number (%).
SM, submucosa.
Table 2 Characteristics of Patients with Non-curative Endoscopic Resection (n=7)
Variable | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
---|---|---|---|---|---|---|---|
Sex | Male | Female | Male | Female | Male | Male | Male |
Age, yr | 56 | 49 | 64 | 62 | 71 | 62 | 64 |
Tumor location | Middle | Lower | Middle | Upper | Middle | Middle | Middle |
Tumor size, mm | 15 | 15 | 5 | 20 | 24 | 32 | 32 |
Histology | Differentiated | Differentiated | Differentiated | Differentiated | Differentiated | Differentiated | Undifferentiated |
Non-curative factor | SM2 invasion | LM positive | SM2 invasion | SM2 invasion | SM2 invasion | LM positive | SM2 invasion |
Resection type | |||||||
Perforation | Microperforation | Microperforation | Microperforation | Macroperforation | Macroperforation | Macroperforation | Macroperforation |
Management of perforation | Conservative care | Endoscopic clipping | Endoscopic clipping | Endoscopic clipping | Emergency operation (wedge resection and primary repair) | Endoscopic clipping | Endoscopic clipping |
Treatment after NCR | Refusing surgery | Refusing surgery | Additive surgery (gastrectomy with LN dissection) | Refusing surgery | Emergency operation (wedge resection and primary repair) | Additive surgery (gastrectomy with LN dissection) | Additive surgery (gastrectomy with LN dissection) |
Follow-up, mo | 98 | 59 | 49 | 84 | 28 | 51 | 36 |
Recurrence | No | No | No | No | Yes | No | No |
Peritoneal seeding | No | No | No | No | Yes | No | No |
Survival | Yes | Yes | Yes | Yes | No | Yes | Yes |
SM, submucosa; LM, lateral margin; NCR, non-curative resection; LN, lymph node.
Table 3 Univariate Analysis of Clinicopathologic Characteristics Associated with Cancer Recurrence
Characteristic | No recurrence | Recurrence | p-value |
---|---|---|---|
Age, yr | 0.143 | ||
<65 | 222 (43.6) | 9 (30.0) | |
≥65 | 287 (56.4) | 21 (70.0) | |
Sex, male:female | 363:146 | 22:8 | 0.812 |
Tumor location | 0.083 | ||
Upper | 31 (6.1) | 4 (13.3) | |
Middle | 124 (24.4) | 3 (10.0) | |
Lower | 354 (69.5) | 23 (76.7) | |
Tumor size, mm | <0.001 | ||
<20 | 301 (59.1) | 3 (10.0) | |
20–30 | 143 (28.1) | 18 (60.0) | |
>30 | 65 (12.8) | 9 (30.0) | |
Macroscopic type | 0.197 | ||
Elevated | 201 (39.5) | 12 (40.0) | |
Flat | 138 (27.1) | 12 (40.0) | |
Depressed | 170 (33.4) | 6 (20.0) | |
Histology | 0.431 | ||
Differentiated | 463 (91.0) | 26 (86.7) | |
Undifferentiated | 46 (9.0) | 4 (13.3) | |
Depth of invasion | |||
Mucosa | 431 (84.6) | 24 (80.0) | 0.783 |
SM1 (<500 µm) | 41 (8.1) | 3 (10.0) | |
SM2 (≥500 µm) | 37 (7.3) | 3 (10.0) | |
Lymphovascular invasion | 0.431 | ||
Absent | 473 (92.9) | 29 (96.7) | |
Present | 36 (7.1) | 1 (3.3) | |
Curative resection | <0.001 | ||
Yes | 374 (73.5) | 11 (36.7) | |
No | 135 (26.5) | 19 (63.3) | |
Perforation | |||
Yes | 33 (6.5) | 1 (3.3) | 0.490 |
No | 476 (93.5) | 29 (96.7) |
Data are presented as number (%).
SM, submucosa.
Table 4 Multivariate Analysis of Clinicopathologic Characteristics Associated with Cancer Recurrence
Characteristic | OR (95% CI) | p-value |
---|---|---|
Tumor size, mm | ||
<20 | Reference | - |
20–30 | 9.97 (2.83–35.07) | <0.001 |
>30 | 8.17 (2.01–33.19) | 0.003 |
Curative resection | ||
Yes | Reference | - |
No | 2.73 (1.20–6.25) | 0.017 |
OR, odds ratio; CI, confidence interval.